Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) Income towards Parent Company (2016 - 2018)

Armata Pharmaceuticals' Income towards Parent Company history spans 6 years, with the latest figure at -$1.1 million for Q4 2018.

  • For Q4 2018, Income towards Parent Company fell 122.68% year-over-year to -$1.1 million; the TTM value through Dec 2018 reached -$10.0 million, down 73.63%, while the annual FY2024 figure was -$53.2 million, 22.71% down from the prior year.
  • Income towards Parent Company for Q4 2018 was -$1.1 million at Armata Pharmaceuticals, up from -$2.8 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $4.9 million in Q4 2017 and bottomed at -$11.3 million in Q1 2014.
  • The 5-year median for Income towards Parent Company is -$2.9 million (2018), against an average of -$3.2 million.
  • The largest annual shift saw Income towards Parent Company plummeted 691.25% in 2014 before it skyrocketed 231.26% in 2017.
  • A 5-year view of Income towards Parent Company shows it stood at -$2.6 million in 2014, then rose by 6.51% to -$2.4 million in 2015, then crashed by 52.31% to -$3.7 million in 2016, then surged by 231.26% to $4.9 million in 2017, then crashed by 122.68% to -$1.1 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's Income towards Parent Company are -$1.1 million (Q4 2018), -$2.8 million (Q3 2018), and -$3.0 million (Q2 2018).